ClinicalTrials.gg
RecruitingNCT06212947Updated Apr 3, 2025

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

An observational study in Hypochondroplasia, sponsored by BioMarin Pharmaceutical. Recruiting at 43 sites in 11 countries. Open to participants aged Up to 15 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by BioMarin Pharmaceutical · Observational

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
Up to 15 Years
Sex
All
01

Study summary

This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

02

Conditions studied

  • Hypochondroplasia
03

In context

Lead sponsor

BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include approximately 400 pediatric individuals with hypochondroplasia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≤ 15 years old at the time of signing the
  • Participants must have genetic confirmation of Hypochondroplasia diagnosis

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of another genetic short stature condition other than Hypochondroplasia or a genetic variant known to cause another genetic syndrome associated with short stature
  • Received an product or medical device within 6 months before the Screening visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children with Hypochondroplasia

    Children with Hypochondroplasia

06

What researchers measure

Primary outcomes

  1. Change in annualized growth velocity (AGV)

    Time frame: Every 6 months through end of study, up to 15 years

  2. Change in Height Z-score

    Time frame: Every 6 months through end of study, up to 15 years

  3. Change in Height

    Time frame: Every 6 months through end of study, up to 15 years

  4. Change in BMI

    Time frame: Every 6 months through end of study, up to 15 years

  5. Change in BMI Z-score

    Time frame: Every 6 months through end of study, up to 15 years

  6. Change in ratios of upper to lower body segments

    Time frame: Every 6 months through end of study, up to 15 years

  7. Change in ratios of upper and lower leg length ratio

    Time frame: Every 6 months through end of study, up to 15 years

  8. Change in ratio of arms span to standing height ratio

    Time frame: Every 6 months through end of study, up to 15 years

Secondary outcomes

  1. Change in Quality of Life in Short Statured Youth (QoLISSY) physical domain

    Time frame: Every 52 weeks through end of study, up to 15 years

  2. Change in Quality of Life in Short Statured Youth (QoLISSY) total score

    Time frame: Every 52 weeks through end of study, up to 15 years

  3. Change in patient global impression of severity (PGI-S)

    Time frame: Every 52 weeks through end of study, up to 15 years

  4. Change in caregiver global impression of severity (CaGI-S)

    Time frame: Every 52 weeks through end of study, up to 15 years

  5. Frequency of event rates of medical events of interest

    Time frame: Every 6 months through end of study, up to 15 years

  6. Proportion of children who report use of growth hormone, treatment patterns and impact on growth

    Time frame: Every 6 months through end of study, up to 15 years

  7. Proportion of children who report limb lengthening surgery

    Time frame: Every 6 months through end of study, up to 15 years

07

Study locations

32 of 43 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2043, 241 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Jan 19, 2024
StartActual
Nov 27, 2023
Primary completionEst.
Dec 31, 2043
CompletionEst.
Dec 31, 2043
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06212947
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Nov 27, 2023
Primary completion
Dec 31, 2043 (estimated)
Completion
Dec 31, 2043 (estimated)
Last update
Apr 3, 2025

Study contacts

Trial Specialist
Contact
medinfo@bmrn.com
1-800-983-4587
Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion